SEC Form AW filed by Titan Medical Inc.

TORONTO, ON, March 09, 2023 (GLOBE NEWSWIRE) -- Titan Medical Inc. (the "Company" or "Titan") (NASDAQ:TMDI, TSX:TMD) today announced that it has received a decision of the Nasdaq Hearings Panel (the "Panel") advising the Company that effective at the open of business on March 10, 2023, the Company's common shares will be delisted from The Nasdaq Stock Market ("Nasdaq"). On December 30, 2021, Nasdaq Listing Qualifications staff ("Staff") issued the Company a deficiency notice citing its failure to comply with the minimum bid price requirement under Listing Rule 5550(a)(2) (the "Rule"). In accordance with Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until June

Toronto, Ontario, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Titan Medical Inc. (the "Company" or "Titan") (NASDAQ:TMDI, TSX:TMD) today announced senior leadership changes and the receipt of a notification from the Nasdaq Stock Market LLC Listing Qualifications Department stating that following the resignation of Heather Knight from the Company's board of directors and audit committee, the Company no longer complies with Nasdaq's audit committee requirement set forth in Nasdaq Rule 5605. Senior Leadership Changes Following the announcement of February 8, 2023, the Company has decided to layoff certain members of the Company's senior leadership team. Each of these individuals remain available to a

TORONTO, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Titan Medical Inc. (the "Company" or "Titan") (NASDAQ:TMDI, TSX:TMD) today provided an update on the previously announced review and evaluation of strategic alternatives. As previously disclosed on November 30, 2022, Titan's Board of Directors determined that it was in the best interests of the Company and its stakeholders to undertake a review and evaluation of strategic alternatives and engaged Raymond James as the Company's financial advisor. At the direction of the Board, Titan's financial advisor and members of Titan's leadership team conducted a comprehensive outreach to over 40 potential counterparties, engaged in a number of management p

Oppenheimer initiated coverage of Titan Medical with a rating of Outperform and set a new price target of $4.00

15-15D - TITAN MEDICAL INC (0000840551) (Filer)

EFFECT - TITAN MEDICAL INC (0000840551) (Filer)

EFFECT - TITAN MEDICAL INC (0000840551) (Filer)

TORONTO, ON, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. ((Nasdaq: TMDI, TSX:TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced that Eric Heinz has been appointed as the company's Vice President, Market and Corporate Development. Mr. Heinz will be responsible for developing and executing on strategic business plans to expand and accelerate Titan's Enos™ robotic single access surgical system's portfolio cadence. He will also lead existing partnerships and look to supplement those to maximize Titan's reach and the utilization of the Enos system. Mr. Hei

TORONTO, June 30, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. ((Nasdaq: TMDI, TSX:TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced that Cary G. Vance has been appointed as the company's President and CEO effective July 1, 2022. Mr. Vance will succeed Paul Cataford, Titan's chair of the board of directors, who has served as Interim President and CEO since December 2021. Mr. Vance previously served as President and CEO at Xcath Incorporated, a privately held neurovascular robotics company, and held similar positions at Optiscan Biomedical, and Myoscience. He a

TORONTO, June 09, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. ((Nasdaq: TMDI, TSX:TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced the voting results form the company's Annual and Special Meeting of its shareholders held on Wednesday June 8, 2022. All of management's nominees for election were duly elected as directors of the company by the shareholders presented or represented by proxy at the meeting. A total of 54,760,905 of the 111,202,690 common shares outstanding, or 49.24%, were voted at the meeting. The results of the vote were reported to the meeting

TORONTO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (NASDAQ:TMDI, TSX:TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced financial results for the three and nine months ended September 30, 2022. Additionally, the company announced that a special meeting of shareholders will be held virtually on January 12, 2023 to seek shareholder approval for a consolidation of its common shares, including for the purposes of demonstrating compliance with Nasdaq Rule 5550(a)(2). As previously shared, Nasdaq granted the company with an extension to regain compliance

TORONTO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (NASDAQ:TMDI, TSX:TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced financial results for the three and six months ended June 30, 2022. "I am thrilled to lead Titan Medical as President and CEO and have been committed to the company's mission to improve surgical outcomes as a director of the company since September 2020. We continue to make progress on impacting the future of minimally invasive robotic surgery and the operating room ecosystem. Our technical partnerships, our relationships with surg

Manufacturing Team and Capabilities Continue to Expand Titan Medical Inc. (NASDAQ:TMDI, TSX:TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced financial results for the three months ended March 31, 2022. "The entire team is focused on driving performance and progress supporting our IDE application submission milestone. We are also starting to prepare for the forthcoming commercialization of the Enos single-access RAS platform for gynecological surgery, our initial target indication for use," stated Paul Cataford, Interim President, CEO and Board Chair. "We are